Jazz Pharmaceuticals settles with indirect purchasers in US Xyrem antitrust case
MLex Summary: Jazz Pharmaceuticals agreed to pay $145 million to resolve US antitrust claims filed by indirect purchasers of Xyrem, according to a filing with the Securities and Exchange Commission. The...To view the full article, register now.
Already a subscriber? Click here to view full article